Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA)

Rusconi, S;Adorni, F;Bruzzone, B;Di Biagio, A;Meini, G;Callegaro, A;Punzi, G;Boeri, E;Pecorari, M;Monno, L;Gianotti, N;Butini, L;Galli, L;Polilli, E;Galli, M;ARCA Collaborative Group;Mandas, A

Member of the Collaboration Group

2013-01-01

---

Abstract

The prevalence of drug resistance associated with the failure of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens and the predictors of resistance to Etravirine (ETR) were assessed in 2854 subjects: 39<18 (paediatric) and 281518 (adult) years old. These subjects failed to respond to their current NNRTI treatment, were three-class experienced and had been exposed to NNRTI for 3months. A total of 1827 adult (64.9%) and 32 paediatric subjects (82.1%) harboured the virus with at least one ETR mutation. V179I, Y181C and G190A were the most frequent mutations in both groups. A significantly increased risk of ETR resistance with all three algorithms (Monogram (MGR) >3, Tibotec (TBT) >2 and enhanced MGR (ENH) 4) emerged in the paediatric population. Multivariate analysis revealed an increased risk of developing TBT >2 for NNRTI exposure, ENH 4 for NNRTI and EFV exposure in paediatric subjects; NVP exposure and higher (3.5 log10) HIV-RNA values for all three algorithms in adult subjects, whereas CD4200/L appeared to be protective. The risk of being ETR resistant was more than doubled for paediatric vs. adult subjects, probably due to a more extensive use of NNRTI and an incomplete virological control.